DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical
care. Without phasing information (ie, allelic location of variants), current genotype-based …

Fluoropyrimidine drugs (FPs), including 5-fluorouracil, tegafur, capecitabine, and
doxifluridine, are among the most widely used anticancer agents in the treatment of solid …

Objective Certain polymorphisms of the DPYD gene encoding for the dihydropyrimidine
dehydrogenase (DPD) enzyme are associated with fluoropyrimidine-induced toxicity. Dose …

Background Fluoropyrimidine chemotherapy is used across many tumor types and settings.
The incidence of severe adverse events (SAEs) is around 20%. Mortality is 0.5%-1 …

Background: Fluoropyrimidines are widely used in the treatment of solid tumors and remain
the backbone of many combination chemotherapy regimens. Despite their clinical benefit …

Fluoropyrimidines are chemotherapy drugs that may cause severe adverse events, and their
metabolism occurs by dihydropyrimidine deydrogenase (DPD), coded by DPYD. Variants in …

Background 5-Fluorouracil (5-FU) is an agent frequently used in the treatment of solid
cancers. A deficiency in the enzyme that catabolizes 5-FU leads to severe toxicity. The gene …

2 Background In 2015, the newly formed Therapeutic Drug Monitoring (TDM) in Oncology
Scientific Committee of the IATDMCT convened a meeting in Rotterdam, The Netherlands, to …

Fluoropyrimidines (FP) are given in the combination treatment of the advanced disease or
as monotherapy in the neo-adjuvant and adjuvant treatment of colorectal cancerand other …

Fluoropyrimidines are widely used in the treatment of solid tumors, mainly gastrointestinal,
head and neck and breast cancer. Dihydropyrimidine dehydrogenase (DPD) is the rate …